Results 151 to 160 of about 360,869 (356)
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. [PDF]
J Clin OncolGore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group. +49 moreeuropepmc +1 more sourceUpdate and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children.
European UrologyM. Gnech, L. '. 't Hoen, Alexandra Zachou, G. Bogaert, M. Castagnetti, F. O’Kelly, J. Quaedackers, Y. Rawashdeh, M. Sılay, U. Kennedy, M. Skott, A. van Uitert, Yuhong Yuan, C. Radmayr, B. Burgu +14 moresemanticscholar +1 more sourceEnfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis
International Journal of Cancer, EarlyView.What's New?
New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler +30 morewiley +1 more sourceDisproportionately low authorship by women urologists in sexual medicine journals. [PDF]
Sex MedSaxena S, Peta A, Raver M, Gelman S, Yang M, Abdel-Wahab M, Holbrook N, Zhang S, Chen J, Brink S, Shin D. +10 moreeuropepmc +1 more sourceEuropean Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era
European Urology, 2020 M. Ribal, P. Cornford, A. Briganti, T. Knoll, S. Gravas, M. Babjuk, C. Harding, A. Breda, A. Bex, J. Rassweiler, A. Gözen, G. Pini, E. Liatsikos, G. Giannarini, A. Mottrie, R. Subramaniam, N. Sofikitis, B. Rocco, Lijiao Xie, J. Witjes, N. Mottet, B. Ljungberg, M. Rouprêt, M. P. Laguna, A. Salonia, G. Bonkat, B. Blok, C. Türk, C. Radmayr, N. Kitrey, D. Engeler, N. Lumen, O. Hakenberg, N. Watkin, Rizwan Hamid, J. Olsburgh, J. Darraugh, R. Shepherd, E. Smith, C. Chapple, A. Stenzl, H. van Poppel, M. Wirth, J. Sønksen, J. N'Dow +44 moresemanticscholar +1 more sourceHead‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT
International Journal of Cancer, EarlyView.What's New?
The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group +15 morewiley +1 more source
